Glomerular permselectivity in proteinuric patients after kidney transplantation

Dextran fractional clearance studies in acute dengue infection

Background

Although increased capillary permeability is the major clinical feature associated with severe dengue infections the mechanisms underlying this phenomenon remain unclear. Dextran clearance methodology has been used to investigate the molecular sieving properties of the microvasculature in clinical situations associated with altered permeability, including during pregnancy and in various renal disorders. In order to better understand the characteristics of the vascular leak associated with dengue we undertook formal dextran clearance studies in Vietnamese dengue patients and healthy volunteers.

Methodology/Principal Findings

We carried out serial clearance studies in 15 young adult males with acute dengue and evidence of vascular leakage a) during the phase of maximal leakage and b) one and three months later, as well as in 16 healthy control subjects. Interestingly we found no difference in the clearance profiles of neutral dextran solutions among the dengue patients at any time-point or in comparison to the healthy volunteers.

Conclusions/Significance

The surface glycocalyx layer, a fibre-matrix of proteoglycans, glycosaminoglycans, and plasma proteins, forms a complex with the underlying endothelial cells to regulate plasma volume within circumscribed limits. It is likely that during dengue infections loss of plasma proteins from this layer alters the permeability characteristics of the complex; physical and/or electrostatic interactions between the dextran molecules and the glycocalyx structure may temporarily restore normal function, rendering the technique unsuitable for assessing permeability in these patients. The implications for resuscitation of patients with dengue shock syndrome (DSS) are potentially important. It is possible that continuous low-dose infusions of dextran may help to stabilize the permeability barrier in patients with profound or refractory shock, reducing the need for repeated boluses, limiting the total colloid volume required. Formal clinical studies should help to assess this strategy as an alternative to conventional fluid resuscitation for severe DSS.

Dengue is a potentially serious common viral infection with no specific treatment. Plasma leakage from small blood vessels is the major severe problem, but we do not understand how this occurs. Techniques using controlled infusions of carbohydrate solutions, combined with careful measurement of the rate that the different-sized molecules clear from the circulation, have been successfully used to investigate leakage in other situations. We performed carbohydrate clearance studies in 15 Vietnamese adult males with dengue and plasma leakage, comparing results obtained during the acute illness with recovery values, and results from a group of healthy volunteers. However, we found no differences between any of the clearance profiles measured. One possible explanation may be that the carbohydrate molecules interact with blood vessels, temporarily restoring their normal barrier function. Although this means that the technique is unsuitable for investigating leakage in dengue patients, the implications for management of patients with severe leakage resulting in shock are potentially important. Patients with profound shock are usually managed with intermittent large boluses of carbohydrate or similar solutions, sometimes causing severe side-effects; however if continuous low-dose infusions actually stabilized the permeability barrier, this might reduce the need for repeated boluses, thereby minimizing these adverse effects.

Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction

BACKGROUND

Sirolimus (SRL) is a potent and specific immunosuppressive drug used in organ transplantation, as basic therapy or in combination with calcineurin inhibitors. Although SRL is a nonnephrotoxic drug, many reports have related its use with the development of proteinuria, especially after conversion. Therefore, the aim of this study was to elucidate the interrelation between early and late SRL administration on the development of glomerular hypertrophy and proteinuria in a model of renal mass reduction (RMR).

METHODS

Rats underwent 2/3 cryoablation of the left kidney and subsequent right nephrectomy (n=42) or sham operations (n=29). Two weeks before (early study) or 12 weeks after (late study) surgery, SRL or vehicle was administered three times weekly. Creatinine clearance and proteinuria were determined throughout the study, and a complete histologic analysis was performed at the end of the study.

RESULTS

Treatment with SRL had no effect on creatinine clearance, independently of the administration time. Four weeks after RMR, a significant increase in proteinuria was observed. Proteinuria was stabilized after early and late SRL administration, whereas vehicle-treated animals showed a further increase in proteinuria. Glomerular hypertrophy was strongly associated with proteinuria, and early SRL introduction prevented glomerular enlargement. The histologic analysis showed less structural damage in the two groups of animals treated with SRL than in the control group.

CONCLUSION

Although early SRL introduction blocked glomerular hypertrophy, SRL treatment revealed the potential to halt progression of proteinuria and histologic damage at any time of administration in a model of RMR.

Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation

BACKGROUND

Calcineurin inhibitor(CNI)-free protocols using sirolimus (SRL) in kidney transplantation have proven effective, although reports have linked SRL to proteinuria. We sought to investigate this link and its impact on graft function.

METHODS

We retrospectively analyzed 184 live donor kidney transplant recipients who exclusively received de novo CNI-based (n = 106) or SRL-based (n = 78) regimens. Estimated glomerular filtration rate (GFR) and semi-quantitative dipstick proteinuria measurements were obtained at one, six, 12, and 24 months and six and 12 months, respectively.

RESULTS

SRL-treated patients had higher frequencies of proteinuria (> or =1+) at 6 months (40.8% vs. 21.4%, P = 0.006) and 12 months (37.8% vs. 18.4%, P = 0.004) than those treated with CNI. Independent predictors of proteinuria at 12 months were GFR at one month (OR 0.62 per 10 ml/min/1.73 m, P<0.001), delayed graft function (OR 11.5, P = 0.02), and a SRL-based regimen (OR 4.18, P=0.002). By univariable analysis, SRL vs. CNI patients had higher GFR at each point. SRL-treated patients without proteinuria had higher GFR at 12 months compared to CNI-treated patients with and without proteinuria (66 vs. 50 or 56 ml/min/1.73 m, P < 0.05). No difference in GFR was seen between SRL-treated patients with proteinuria vs. CNI-treated patients without proteinuria (57 vs. 56 ml/min/1.73 m, P > 0.05). Absence of proteinuria and a SRL-based regimen remained independently associated FS with higher GFR at 12 months by multivariable analyses.

CONCLUSIONS

De novo SRL-based immunosuppression is associated with a higher frequency of semi-quantitative proteinuria, however, estimated graft function at 1 year posttransplant remains superior to that of CNI-treated patients. Nevertheless, the long-term implications of these findings need to be determined.

Effects of Candesartan on Glomerular Hemodynamics and Permselectivity in Patients with Favorable Renal Allograft Function

BACKGROUND

Distinct effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers on glomerular perfusion and permselectivity are important determinants of the substances nephroprotective quality. In renal allograft recipients, however, specific effects of angiotensin antagonism on glomerular function have not been evaluated so far.

METHODS

Twenty patients with favorable allograft function were included into a prospective study within the first year after renal transplantation. Glomerular filtration rate, renal plasma flow, albuminuria, and the fractional clearances of neutral dextrans were determined at baseline and after 3 months of treatment with candesartan. Ten individuals after renal donation served as controls for the baseline evaluation.

RESULTS

Compared with the control group, the allograft recipients had a higher renal-vascular resistance and a lower glomerular filtration rate. Albuminuria was significantly higher; however, the difference in the dextran sieving curve was not statistically significant. Apart from mild changes in biochemical parameters, the therapy with candesartan led to a rise in serum creatinine along with a nonsignificant drop in the glomerular filtration rate. There was a highly significant drop in filtration fraction and albuminuria. Glomerular permselectivity clearly improved for a range of dextran molecular diameters from 43 Angstrom up to 73 Angstrom.

CONCLUSION

A therapy with candesartan has distinct effects on glomerular function in patients after renal transplantation. A drop in filtration fraction along with an improvement in glomerular permselectivity and albuminuria point to a nephroprotective quality that should lead to a systematic clinical evaluation of candesartan even in patients with favorable renal allograft function.

Early glomerular dysfunction in human renal allografts

BACKGROUND

The long-term outcome of renal allografts is characterized by a progressive deterioration of renal function and graft loss. Our aim was to determine early glomerular functional abnormalities, before they become clinically apparent.

METHODS

Glomerular hemodynamics and dextran sieving were characterized in 21 well-functioning cadaveric renal allograft recipients [normal glomerular filtration rate (GFR) and albumin excretion rate (AER), who also had a kidney biopsy with normal or minimal histological changes] and in 15 uninephrectomized kidney donors. Both groups were one to three years after transplantation or uninephrectomy.

RESULTS

The GFR and renal plasma flow (RPF) were similar in both groups (62 +/- 3 vs. 63 +/- 4, and 343 +/- 26 vs. 334 +/- 21 mL/min/1.73 m2 for GFR and RPF, in cadaveric recipients vs. donors, respectively), the AER was normal in both groups, but the mean arterial pressure was higher in renal recipients (103 +/- 3 vs. 94 +/- 3 mm Hg in uninephrectomy controls, P < 0.05). Despite similar levels of overall glomerular function in the two groups, the dextran sieving curve was uniformly elevated in the renal allograft recipients versus uninephrectomy controls (P < 0.05 for dextrans 38 to 66 A). Using a log-normal glomerular pore-size distribution model to analyze potential mechanisms, the elevation in the dextran sieving curve resulted from a shift in the distribution of glomerular filtering pores to a larger size (mean glomerular pore size 46 +/- 2 vs. 43 +/- 2 A for uninephrectomy controls, P < 0.05), resulting in a larger fraction of filtrate volume permeating very large pores. By morphometric analysis, the thickness of the glomerular basement membrane was increased in kidney allograft as compared to 2-kidney biopsy controls (614 +/- 33 vs. 427 +/- 22 nm, respectively, P < 0.05).

CONCLUSIONS

Even in "well functioning" renal allografts there is a glomerular dysfunction characterized by increased permeability to macromolecules resulting from a shift of the glomerular pores to a larger size. These changes could be mediated by ultrastructural alterations at the glomerular capillary or by alterations in intraglomerular hemodynamics. Early allograft dysfunction may contribute to the progressive renal insufficiency of renal allografts.

High-performance liquid chromatographic determination of p-aminohippuric acid and iothalamate in human serum and urine: comparison of two sample preparation methods

A high-performance liquid chromatography method applied to determine p-aminohippuric acid (PAH) and iothalamate (IOT) in serum and urine samples of patients was evaluated according to recovery, reproducibility and linearity utilizing narrow-bore columns. The mobile phase consisted of 0.15 M sodium dihydrogenphosphate with 1.2 mM tetrabutylammonium sulphate, the pH was adjusted to pH 4.6, acetonitrile was added to a final ratio of 95:5 (v/v), the flow-rate was set at 0.3 ml/min. The separation was achieved on a ODS Hypersil column (200 x 2.1 mm I.D.). The UV detector was set at 254 nm. PAH and IOT are used for evaluation of kidney function [effective renal plasma flow (ERPF) and glomerular filtration rate (GFR)]). Under the described chromatographic conditions two sample preparation techniques, ultrafiltration and acetonitrile precipitation were compared. The results demonstrate the accuracy of both methods in evaluation of ERPF and GFR. Due to its cost-effectiveness we recommend the acetonitrile precipitation method in clinical routine.

Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure

Excessive neurohumoral activity remains a major burden to the circulation of patients with advanced heart failure. Prostaglandin E1 (PGE1), a balanced i.v. vasodilator, was shown to elicit favorable hemodynamic and clinical effects in this cohort. A prospective randomized parallel group trial was performed to evaluate acute, intermediate and chronic changes in hemodynamic, neurohumoral and renal variables in response to PGE1, dobutamine and placebo. Thirty patients with class III and IV heart failure and low cardiac index (mean 1.9 l/min/m2) two hours after oral drugs including high dose enalapril were included. A 7-day-infusion of PGE1 (16.5 +/- 5 ng/kg/min, range 10 to 20 ng/kg/min, group A n = 10), dobutamine (4.5 +/- 1 micrograms/kg/min, range 2.5 to 5 micrograms/kg/min, group B n = 10) or placebo (saline, group C n = 10) was administered via a central venous access line after stepwise titration until intolerable side effects developed with PGE1 or a 20% increase in cardiac index occurred with dobutamine, which was continued on this dose throughout while PGE1 was maintained on 50% peak dose. Hemodynamic data were collected at baseline, at peak dosages, after 12 hours and after 7 days. Of neurohumoral variables plasma norepinephrine, big endothelin (Big ET) and atrial natriuretic peptide (ANP) were simultaneously evaluated using RIA methods. Renal plasma flow (by paraaminohippurate clearance) and glomerular filtration rate (by iothalamate clearance) was measured prior to and during the infusions (after 12 hours and after 7 days). At peak dose and at 12 hours significant drops from baseline of mean pulmonary artery pressure, pulmonary capillary wedge pressure and systemic vascular resistance were observed which were accompanied by a rise in cardiac output with both PGE1 and dobutamine. These changes were maintained through 7 days when pulmonary vascular resistance levels also fell with both active drugs. Blood pressure did not change throughout, but PGE1 increased heart rate slightly at 12 hrs. Both PGE1 and dobutamine enhanced renal plasma flow after 7 days, but only PGE1 decreased glomerular filtration fraction significantly. Glomerular filtration rate did not change with either drug. PGE1 decreased ANP levels at 12 hrs, and dobutamine increased big ET levels at peak, but decreased big ET at 7 days. Norepinephrine levels were unaffected throughout. Except a slight decrease in right atrial pressure after 7 days placebo did not change any measured variable significantly. Taken together, these data suggest that treatment with PGE1 is as efficacious as low-dose dobutamine in improving cardiac performance and renal perfusion in advanced heart failure. Of importance, no deleterious neurohumoral counterregulation was observed with PGE1.

Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients

In this study, we determined the fractional clearance of neutral polydisperse dextrans (theta D) and monodisperse dextran sulfate (theta DS) to describe glomerular size and charge selectivity in 25 renal transplant recipients with proteinuria. Thirteen were treated with low dose lisinopril for six months (group 1) and 12 patients without ACE inhibitor therapy formed group 2. Mean arterial blood pressure was stable (group 1, 112 +/- 4; group 2, 109 +/- 2 mm Hg at baseline and after 6 months) whereas creatinine clearance, glomerular filtration rate and renal plasma flow decreased nonsignificantly but were comparable at any time. Lisinopril treatment lowered filtration fraction (22 +/- 2 vs. 19 +/- 2%, P = 0.07) whereas no change was seen in group 2 (20 +/- 2%). The fractional protein excretion (mg urinary protein per day/ml creatinine clearance per day) was stable in group 1, but significantly increased in group 2. The same pattern was found for theta D larger than 56 A. theta DS was stable and consistently elevated in both groups at any time. We conclude that low dose ACE inhibitor treatment in proteinuric renal transplant recipients stabilizes glomerular size selectivity independently of its systemic hemodynamic effects.

Renal function and glomerular permselectivity late after living related donor transplantation

Living related kidney transplantation is the preferable procedure for renal replacement therapy. The aim of the current study was to determine systemic hemodynamic and intrarenal adaptions in donors and recipients late after living related kidney transplantation. Furthermore, glomerular permselectivity was assessed in these subjects. We studied mean blood pressure (MAP), glomerular filtration rate (GFR), renal plasma flow (RPF), microalbuminuria (MIA), 24-hr urinary protein excretion, and glomerular permselectivity (fractional clearance of neutral dextrans [thetaD] as a marker for size selectivity and fractional clearance of dextran sulfate [thetaDS] to assess charge selectivity) in 22 donors and 22 recipients. MAP was normal in the donor group (102 +/- 4 mmHg), but five patients had blood pressure above 140/90 mmHg. This 18%, however, is lower than the prevalence of hypertension in the age-adjusted general population in Austria. The recipients also had normal MAP at the time of study (99 +/- 3); however, 13 needed antihypertensive therapy. GFR and RPF were lower in recipients than in donors (53 +/- 8 vs. 72 +/- 11 and 314 +/- 74 vs. 412 +/- 86 ml/min respectively). In the donor group, GFR was 137 +/- 45% of the expected age-adjusted mean value/kidney due to hyperfiltration. Proteinuria and MIA were higher in the recipients than in the donors (0.39 +/- 0.22 vs. 0.07 +/- 0.04 g/day, 137 +/- 136 vs. 26 +/- 15 mg/day). Nonetheless, five donors had an elevated MIA. A higher need for antihypertensive medication could be observed in recipients with previous rejection episodes, as well as a significantly higher urinary protein excretion and MIA (0.7 +/- 0.42 vs. 0.24 +/- 0.14 g/day, 336 +/- 380 vs. 48 +/- 32 mg/day). ThetaDS was significantly higher in the recipients, whereas thetaDS of the donors was identical to the value obtained from 18 healthy controls (0.7 +/- 0.08 vs. 0.6 +/- 0.06). OD was similar in all groups studied. In conclusion, 76 months after uninephrectomy for renal donation, mild changes in glomerular permselectivity occurred in a subset of donors without affecting renal excretory function. In recipients, proteinuria was due to a defect in glomerular charge selectivity.